Determinants of HIV-1 virologic suppression in HIV-associated tuberculosis in Brazil
Memórias do Instituto Oswaldo Cruz · 2026 · 121
DOI: 10.1590/0074-02760250090 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Memórias do Instituto Oswaldo Cruz, 2026. Verfasst von Felipe Ridolfi und 22 weiteren Autor:innen. Beteiligte Einrichtung: Vanderbilt University Medical Center, Department of Medicine, Division of Infectious Diseases, Nashville, TN, USA. Hauptthemen laut MEDLINE: HIV-1, HIV Infections, Anti-HIV Agents, Tuberculosis. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, DECIT/SCTIE/MS, NIH/NIAID.
Abstract (Originalsprache)
BACKGROUND Tuberculosis/human immunodeficiency virus (TB/HIV) coinfection is associated with advanced HIV disease and variable responses to antiretroviral therapy (ART). OBJECTIVES We examined whether baseline HIV severity markers, ART regimes, or human genetic variants influenced HIV-1 virologic suppression in HIV-associated TB. METHODS We included TB/HIV participants from Regional Prospective Observational Research in Tuberculosis (RePORT)-Brazil study, who received standard TB therapy and antiretroviral treatment. The primary endpoint was HIV-1 virologic suppression (≤ 1,000 copies/mL); Baseline characteristics, viral load (VL), CD4 cell count, timing of ART initiation, and ART regimens were included. We genotyped UGT1A1 (rs887829; integrase strand transfer inhibitor-related) and CYP2B6 [rs3745274, rs28399499, rs4803419; efavirenz (EFZ)-related]; all have defined normal, intermediate, and slow genotypes. Genotyping was performed by MassARRAY iPLEX Gold; Kaplan-Meier curves compared time-to-suppression with log-rank tests; Cox proportional hazards models estimated hazard ratios. FINDINGS Among 194 participants, 68% (n = 132) achieved virologic suppression (≤ 1,000 copies/mL). Median time-to-suppression: 84 days [95% confidence interval (CI): 42-125]. Participants with higher baseline viral load (BVL) (≥ 5 log10 copies/mL) had delayed suppression compared with those with lower VL (< 5 log10; log-rank χ² = 75.9; p < 0.001). Individuals with CD4 ≤ 200 cells/µL suppressed more slowly than those with CD4 > 200 cells/µL (log-rank χ² = 29.6; p < 0.001). Participants starting ART before TB treatment achieved suppression faster than ART-naïve individuals (32 vs. 147 days; log-rank χ² = 48.5; p < 0.001). Higher BVL was associated with reduced hazard of suppression [adjusted hazard ratio (aHR) = 0.67; 95% CI: 0.61-0.75], while higher baseline CD4 count increased the hazard of suppression (per 100 cells/µL: aHR = 1.11; 95% CI: 1.01-1.21). ART-naïve status was associated with lower hazard of suppression in univariate analysis (Hazard Ratio = 0.51; 95% CI: 0.36-0.72) but not after adjustment. ART regimen class and pharmacogenetic metabolizer profiles were not significantly associated with virologic suppression. MAIN CONCLUSIONS BVL and CD4 count were the strongest determinants of virologic suppression in TB/HIV patients. Suppression rates were low, and neither ART regimen nor pharmacogenetic profiles significantly influenced the likelihood of suppression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Vanderbilt University Medical Center, Department of Medicine, Division of Infectious Diseases, Nashville, TN, USA.
- Fundação Oswaldo Cruz-Fiocruz, Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, RJ, Brasil.
- Vanderbilt University Medical Center, Department of Biostatistics, Nashville, TN, USA.
- Fundação Medicina Tropical Dr Heitor Vieira Dourado, Manaus, AM, Brasil.
- Universidade do Estado do Amazonas, Manaus, AM, Brasil.
- Universidade Federal do Rio de Janeiro, Faculdade de Medicina, Rio de Janeiro, RJ, Brasil.
Förderung
- NIAID NIH HHS
- DECIT/SCTIE/MS
- NIH/NIAID
- CAPES
Zitieren
APA
Ridolfi, F., Amorim, G., Haas, D. W., Arriaga, M., Staats, C., Cordeiro-Santos, M., Kritski, A. L., Figueiredo, M. C., Andrade, B. B., Sterling, T. R., Rolla, V. C., Regional Prospective Observational Research in Tuberculosis (RePORT)-Brazil Consortium, Benjamin, A., Sant'Anna, F. M., Oliveira, J. G., Marin, J., Rezende, A., Carvalho, A. C., Rocha, M., …, & Turner, M. (2026). Determinants of HIV-1 virologic suppression in HIV-associated tuberculosis in Brazil. Memórias do Instituto Oswaldo Cruz, 121. https://doi.org/10.1590/0074-02760250090
Vancouver
Ridolfi F, Amorim G, Haas DW, Arriaga M, Staats C, Cordeiro-Santos M, et al. Determinants of HIV-1 virologic suppression in HIV-associated tuberculosis in Brazil. Memórias do Instituto Oswaldo Cruz. 2026;121. doi:10.1590/0074-02760250090
BibTeX
@article{Ridolfi2026,
author = {Ridolfi, Felipe and Amorim, Gustavo and Haas, David W and Arriaga, Maria and Staats, Cody and Cordeiro-Santos, Marcelo and Kritski, Afrânio L and Figueiredo, Marina C and Andrade, Bruno B and Sterling, Timothy R and Rolla, Valeria C and Regional Prospective Observational Research in Tuberculosis (RePORT)-Brazil Consortium, Regional Prospective Observational Research in Tuberculosis (RePORT)-Brazil Consortium and Benjamin, Aline and Sant'Anna, Flavia M and Oliveira, Jamile Garcia de and Marin, João and Rezende, Adriana and Carvalho, Anna Cristina and Rocha, Michael and Nogueira, Betânia and Brito, Alexandra and Spener, Renata and Turner, Megan},
title = {Determinants of HIV-1 virologic suppression in HIV-associated tuberculosis in Brazil},
journal = {Memórias do Instituto Oswaldo Cruz},
year = {2026},
volume = {121},
doi = {10.1590/0074-02760250090}
}
EUVIMED